Use este identificador para citar ou linkar para este item:
http://bdtd.uftm.edu.br/handle/tede/662Registro completo de metadados
| Campo DC | Valor | Idioma |
|---|---|---|
| dc.creator | MARQUES, Aline Caroline de Lima | - |
| dc.creator.ID | 36111216813 | por |
| dc.creator.Lattes | http://lattes.cnpq.br/9743171933173862 | por |
| dc.contributor.advisor1 | RODRIGUES JUNIOR, Virmondes | - |
| dc.contributor.advisor1ID | 45813493620 | por |
| dc.contributor.advisor1Lattes | http://lattes.cnpq.br/8909243237236516 | por |
| dc.date.accessioned | 2019-05-31T12:50:58Z | - |
| dc.date.issued | 2018-07-12 | - |
| dc.identifier.citation | MARQUES, Aline Caroline de Lima. Avaliação do perfil sorológico anti-Toxoplasma gondiII de pacientes com doenças autoimunes em uso de medicamentos imunomoduladores biológicos e sintéticos. 2018. 53f. Dissertação (Mestrado em Ciências da Saúde) - Programa de Pós-Graduação em Ciências da Saúde, Universidade Federal do Triângulo Mineiro, Uberaba, 2018. | por |
| dc.identifier.uri | http://bdtd.uftm.edu.br/handle/tede/662 | - |
| dc.description.resumo | A toxoplasmose é uma zoonose de distribuição cosmopolita. Durante sua patogênese a resposta imune é fundamental para controle e contenção parasitária e, por essa razão, a toxoplasmose pode ser agressiva em pacientes expostos à imunossupressão terapêutica, como os bloqueadores do TNF-α utilizados no controle de doenças autoimunes. Neste estudo, o perfil sorológico anti-Toxoplasma gondii foi avaliado em pacientes com doenças autoimunes e que fazem uso de inibidores de TNF-α e drogas sintéticas, através da dosagem de IgM, IgG total, IgG1, IgG2, IgG3 e IgG4. Além disso, a avidez dos anticorpos IgG total e IgG1 foi determinada em pacientes positivos para Toxoplasma gondii através do ELISA. Amostras de soro foram coletadas de 87 indivíduos, 32 pacientes com doenças autoimunes usando drogas sintéticas (SIB), 23 com doenças autoimunes usando bloqueadores de TNF-α (IB) e 32 indivíduos no grupo controle (GC). Pacientes positivos para IgG total apresentaram níveis significativamente mais baixos nos grupos IB e SIB em comparação ao GC (p <0,0001) e concentrações mais altas de IgM no grupo IB em comparação aos grupos SIB e GC (p <0,05). A análise da subclasse de IgG1 revelou níveis séricos menores no grupo IB em comparação ao GC (p <0,05) e a menor correlação positiva com IgG total. No entanto, a sua avidez em pacientes pertencentes ao grupo IB foi significativamente maior em comparação com os pacientes nos grupos SIB e GC. Esses resultados sugerem que a terapia bloqueadora do TNF- α interfere na resposta imune humoral específica do Toxoplasma gondii, afetando diretamente o isótipo IgG1, que é o predominante na resposta específica de Toxoplasma gondii estudada. | por |
| dc.description.abstract | Toxoplasmosis is a zoonosis of cosmopolitan distribution. During the pathogenesis of this condition, the function of the immune system is fundamental for parasitic control and containment, and for this reason, toxoplasmosis can be aggressive in patients exposed to therapeutic immunosuppression, such as TNF blockers used in controlling autoimmune diseases. In this study, the anti-Toxoplasma gondii serological profile was evaluated in patients with autoimmune diseases using TNF inhibitors and synthetic drugs, by measuring IgM, total IgG, IgG1, IgG2, IgG3, and IgG4. Furthermore, the avidity of total IgG and IgG1 antibodies were determined in T. gondii positive patients with an Enzyme-Linked Immunosorbent Assay (ELISA). Serum samples were collected from 87 individuals, 32 patients with autoimmune diseases using synthetic drugs (SD), 23 with autoimmune diseases using TNF-α blockers (BD), and 32 healthy subjects in the control group (CG). IgG positive patients presented significantly lower levels in the BD and SD groups compared to the GC (p < 0.0001) and higher levels of IgM concentration in the BD group compared to the SD and CG (p < 0.05) groups. IgG1 subclass analysis revealed decreased serum levels in the BD group in comparison to the CG (p < 0.05) and the lowest positive correlation with total IgG. However, its avidity in patients belonging to the BD group was significantly higher in comparison to patients in the SD and CG groups. These results suggest that TNF-α blocking therapy interferes with the humoral immune response specific to T. gondii, directly affecting the IgG1 isotype, which is the predominant one in the specific T. gondii response studied. | eng |
| dc.description.sponsorship | Coordenação de Aperfeiçoamento de Pessoal de Nível Superior | por |
| dc.description.sponsorship | Conselho Nacional de Desenvolvimento Científico e Tecnológico | por |
| dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado de Minas Gerais | por |
| dc.format | application/pdf | * |
| dc.thumbnail.url | http://bdtd.uftm.edu.br/retrieve/4168/Dissert%20Aline%20C%20L%20Marques.pdf.jpg | * |
| dc.language | por | por |
| dc.publisher | Universidade Federal do Triângulo Mineiro | por |
| dc.publisher.department | Instituto de Ciências da Saúde - ICS::Programa de Pós-Graduação em Ciências da Saúde | por |
| dc.publisher.country | Brasil | por |
| dc.publisher.initials | UFTM | por |
| dc.publisher.program | Programa de Pós-Graduação em Ciências da Saúde | por |
| dc.relation.references | ABBAS, A.K.; LICHTMAN, A.H.; PILLAI, S. Imunologia Celular & Molecular.Rio de Janeiro - RJ: Elsevier, 6ª ed., 350-352, 2008. ALIBERTI, J. Host persistence: Exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nature Reviews Immunology, 5(2):162-170, 2005. BEGHETTO, E.; BUFFOLANO, W.; SPADONI, A.; DEL PEZZO M.; DI CRISTINA M. Use of an immunoglobulin G avidity assay based on recombinant antigens for diagnosis of primary Toxoplasma gondii infection during pregnancy. Journal of Clinical Microbiology, 41(12): 5414–8, 2003. BERAN, O.; KODYM, P.; MALY, M.; DAVIDOVA, A.; REINVARTOVA, G.; JILICH, D.; MICHAL HOLUB, M.; ROZSYPAL, H. 2015. The Effect of Latent Toxoplasma gondii Infection on the Immune Response in HIV-Infected Patients. BioMed Research International, (2015):1-7, 2015. BERTOZZI, L.C.; SUZUKI, L. A.; ROSSI, C.L..Serological diagnosis of toxoplasmosis: usefulness of IgA detection and IgG avidity determination in a patient with a persistent IgM antibody response to Toxoplasma gondii. Revista do Instituto de Medicina Tropical de São Paulo, 41 (3): 175-177, 1999. BRADFORD, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, vol. 7 (72): 248-54, 1976. CANDOLFI, E.R.; PASTOR, R.; HUBER, D.; FILISETTI, O.; VILLARD. IgG avidity assay firms up the diagnosis of acute toxoplasmosis on the first serum sample in immunocompetent pregnant women. Diagnostic Microbiology and Infectious Disease, 58 (1): 83-88, 2007. CHAUDHRY, S.A.; GAD, N.; KOREN G. Toxoplasmosis and pregnancy. Journal List Canadian Family Physician, 60 (4): 334-336, 2014. CREN, J.B.; BOUVARD, B.; CROCHETTE, N. Cerebral toxoplasmosis and anti-TNFa: a case report. IDCases (5) 40–42, 2016. DAMAS, M.S.; MARTINEC, N.L.; FLEGR, J. Do differences in Toxoplasma prevalence influence global variation in secondary sex ratio? Preliminary ecological regression study. Parasitology, 143(9):1193-203, 2016. DATTOLI, V. C. C.; VEIGA, R.V.; CUNHA, S.S.; PONTES-DE-CARVALHO, L. et al.Oocyst ingestion as an important transmission route of toxoplasma gondii in brazilian urban children. Journal Parasitolgy, 97(6): 1080–1084, 2011. DEL BONO, V.; CANESSA, A.; BRUZZI, P.; FIORELLI, M.A.; TERRAGNA, A. Significance of specific immunoglobulin M in the chronological diagnosis of 38 cases of toxoplasmic lymphadenopathy. Journal of Clinical Microbiology, 27(9): 2133-5, 1989. DUBEY, J.P. Advances in the life cycle of Toxoplasma. International Journal Parasitology, 28 (7):1019–1024, 1998. DUBEY, J.P. The History of Toxoplasma gondii - The First 100 Years. Journal of Eukaryotic Microbiology, 55(6): 467 – 475, 2008. DUBEY, J.P. Toxoplasmosis – a waterborne zoonosis.Veterinary Parasitology, 126 (1-2): 57–72, 2004. DUBEY, J.P., BEATTIE, C.P. Toxoplasmosis of Animals and Man. CRC Press, Boca Raton, 220, 1988. DUBEY, J.P.; LINDSAY, D.S.; SPEER, C.A. Structures of Toxoplasma gondii Tachyzoites, Bradyzoites, and Sporozoites and Biology and Development of Tissue Cysts. Clinical Microbiology Reviews, 11(2): 267 – 299, 1998. DUBEY, J.P.; MILLER, N.L.; FRENKEL, J.K. The Toxoplasma gondii Oocyst From Cat Feces. Journal of Experimental Medicine, 132(4): 636 – 662, 1970. EL-HENAWY, A.A.; HAFEZ, E.A.R.; NABIH, N.; SHALABY, N.M.; MASHALY, M. AntiToxoplasma antibodies in Egyptian rheumatoid arthritis patients. Rheumatology International, 37:785–90, 2017. EL-SAYED, N.M.; ISMAIL, K.A.; BADAWY, A.F.; ELHASANEIN, K.F. In vivo effect of anti-TNF agent (etanercept) in reactivation of latent toxoplasmosis. Journal of Parasitic disease, 40(4):1459-65, 2016. ESPINOZA-OLIVA, M.; AVILA, E.S.; ARTEGA, M.B.; OROZCO, L.V.S.; RAMIREZ, M.L.G. Case Report: Cerebral Toxoplasmosis Infection by Reactivation of T. gondii in Pediatric Patients with HIV. Journal Neuroinfectious Diseases, 2014. FIGUEIRÓ-FILHO, E.A. et al. Acute toxoplasmosis: study of the frequency, vertical tansmission rate and the relationship between maternal-fetal diagnostic tests during pregnancy in a Central-Western state of Brazil. Revista Brasileira de Ginecologia Obstetrícia, 27(8): 442-9, 2005. FILISETTI, D.; CANDOLFI, E. Immune response to Toxoplasma gondii. Annali dell'Istituto Superiore di Sanita, 40 (1): 71-80, 2004. GAZZINELLI, R.T.; ELTOUM, I.; WYNN T.A.; SHER A. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-alpha and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. Journal of Immunology, 151(7):3672, 1993. GAZZINELLI, R.T.; WYSOCKA, M.; HAYASHI, S.; DENKERS, E.Y.; HIENY, S.; CASPAR, P.; TRINCHIERI, G.; SHER, A. Parasite-induced IL-12 stimulates early IFNgamma synthesis and resistance during acute infection with Toxoplasma gondii. Journal of Immunology, 153(6):2533–2543, 1994. GERARDS, A.H.; LATHOUDER, S.; GROOT, E.R.; DIJKMANS, B.A.; AARDEN, L.A. Inhibition of cytokine production by methotrexate. Rheumatology, 42 (10) 1189–1196, 2003. GORGIEVSKI-HRISOHO, M.; GERMANN, D.; MATTER, L. Diagnostic implications of kinetics of immunoglobulin M and A antibody responses to Toxoplasma gondii. Journal of Clinical Microbiology, 34(6): 1506-1511, 1996. GUMPEL, J.M. Cyclophosphamide, gold and penicillamine disease-modifying drugs in rheumatoid arthritis–tailored dosage and ultimate success. Rheumatology Rehabilitation, 15(3):217–220, 1976. HEDMAN, K.; LAPPALAINEN, M.; SODERLUND, M.; HEDMAN, L. - Avidity of IgG in serodiagnosis of infectious diseases. Reviews in Medical Microbiology., 4:123-129, 1993. HOFFMAN, W.; LAKKIS, F.G.; CHALASANI, G. B Cells, Antibodies, and More. clinical Journal of the American Society of Nephrology, v.11(1) 137-54, 2016. HUSKINSON, J.; STEPICK-BIEK, P.N.; ARAUJO, F.G.; THULLIEZ, P.; SUZUKI, Y.; REMINGTON J.S. Toxoplasma Antigens Recognized by Immunoglobulin G Subclasses during Acute and Chronic Infection. Journal of clinical microbiology, 27(9): 2031-2038, 1989. JANEWAY, C.A. JR; MEDZHITOV, R. Innate immune recognition. Annual Review Immunology, 20:197–216, 2002. JANKÚ, J. Pathogensa a pathologica anatomie T. Zv. Vrozaneho kolobou zlute skurney oku normal ne velikem a mikrophtalmickem s nalezem parisitu v sitnici. Cesk Parasitology, 62: 1021-1027, 1923. JOHNSON, L. A Protective Role for Endogenous Tumor Necrosis Factor in Toxoplasma gondii. Infection and Immunity, 60 (5): 1979-1983; 1992. KAWARABAYASHI, M.; AURELIANO, D. P ; RAYMUNDO, M.L; GARCIA, R.A., et al.Freqüência de anticorpos anti-Toxoplasma gondii em mulheres, atendidas nas unidades da rede de saúde pública da região metropolitana de São Paulo (2001-2005). Revista Instituto. Adolfo Lutz, 66(1): 63-67, 2007. LIMA, R.T.Q.; BEZERRA, M.C.; RIBEIRO, A.T.M.; MEDEIROS, M.M.M.C. Perfil do uso de agentes biológicos no tratamento da artrite reumatoide: Experiência do Hospital Universitário Walter Cantídio. Revista de Medicina da UFC, 55 (2): 15-22, 2015. LINDSAY, D.S.; BLAGBURN, B.L.; DUBEY, J.P. Feline toxoplasmosis and importance of the Toxoplasma gondii oocysts. Parasitology, 19, 448–46, 1997. LUFT, B.J.; NAOT, Y.; ARAUJO, F.G.; et al. Primary and reactivated Toxoplasma infection in patients with cardiac transplants: clinical spectrum and problems in diagnosis in a defined population. Annals of Internal Medicine, 99:27-31, 1983. MINEO, J. R.; CAMARGO, M. E.; FERREIRA, A. W.; ALMEIDA, G. Research on IgM anti-Toxoplasma gondii antibodies by using a reverse immunoenzymatic techique. Revista do Instituto de Medicina Tropical de São Paulo, São Paulo, 28 (1): 6-11, 1986. MONTOYA, J.G. Laboratory Diagnosis of Toxoplasma gondii Infection and Toxoplasmosis. The Journal of Infectious Diseases, Vol. 185, S73–S82, 2002. MONTOYA, J.G; LIESENFELD, O. 2004. Toxoplasmosis. Lancet, v. 363 2004. MOTA, L.M.H.; CRUZ, B.A.; BRENOL, C.V.; POLLAK, D.F.; et al. Segurança do uso de terapias biológicas para o tratamento de artrite reumatoide e espondiloartrites. Revista Brasileira de Reumatologia, v. 55, n. 3, p.281–309, 2015. NAOT, Y.; BARNETT, E.V.; REMINGTON, J.S. Method for avoiding false-positive results occurring in immunoglobulin M enzyme-linked immunosorbent assays due to presence of both rheumatoid factor and antinuclear antibodies. Journal of Clinical Microbiology, 14: 73- 8, 1981. NICOLLE, C., MANCEAUX, L. ―Sur un protozoaire nouveau du gondii: toxoplasma‖. Seances Academy Scientific, 148: 369–372, 1909. OSTENSEN, M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. American Journal of Reproductive Immunology, 28(3-4):148-52, 1992. REMINGTON, J.S.; THULLIEZ, P.; MONTOYA, J.G. Recent developments for diagnosis of toxoplasmosis. Journal of Clinical Microbiology, 42(3):941–5, 2004. RIBEIRO, D.P.; FREITAS, M.M.P.; CARDOSO, M.R.D.; PAJUABA, A.C.A.M.; SILVA, N.M.; MINEO, T.W.P.; SILVA, J.S.; MINEO, J.R.; SILVA, D.A.O. CpGODN combined with Neospora caninum lysate, but not with excreted-secreted antigen, enhances protection against infection in mice. Vaccine, 27 (19):2570-2579, 2009. RIBEIRO, A.C.; MUTIS, M.S.; FERNANDES, O. Association of the presence of residual anti Toxoplasma gondii IgM in pregnant women and their respective family groups in Miracema, Northwest Rio de Janeiro, Brazil. Memórias do Instituto Oswaldo Cruz,103 (6): 591-4, 2008. ROBBEN, P.M.; MORDUE, D.G.; TRUSCOTT, S.M.; TAKEDA, K.; AKIRA, S. et al. Production of IL-12 by macrophages infected with Toxoplasma gondii depends on the parasite genotype. Journal of Immunology, 172:3686–3694, 2004. SAYLES, P.C.; GIBSON, G.W.; JOHNSON, L.L. B cells are essential for vaccinationinduced resistance to virulent Toxoplasma gondii. Infection and Immunity, 68(3):1026-33, 2000. SCANGA, C.A.; ALIBERTI, J.; JANKOVIC, D. et al. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. Journal of Immunology, 168:5997, 2002. SCHARTON-KERSTEN, T.M.; YAP, G.; MAGRAM, J.; SHER, A. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. Journal of Experimental Medicine, 185:1261–1273, 1997. SCOTT, P.; PERACE, E.; NATOVITZ, P.; SHER, A. Vaccination against cutaneous leishmaniasis inn a murine model. II Immunologic properties of protective and nonprotective subfractions of soluble promastiogote extract. Journal of Immunology, Baltimore, 139 (1): 221-227,1987. SERT, M.; OZBEK, S.; PAYDAS, S.; YAMAN, A. Is there any relationship between Toxoplasma infection and reactive arthritis? Postgraduate Medical Journal, 53:14–16, 2007. SHARMA, R.; SHAH, N.; CLAUS, J.; PATEL, S.; ZACHARIAH, M. Toxoplasma chorioretinitis following renal transplantation. kidney international, 89: 724, 2016. SHULMAN, I.A. Parasitic infections and their impact on blood donor selection and testing. Archives Pathology Laboratory Medicine, 118:366–70, 1994. SILVA, D.A.A.; SILVA, M.V.; BARROS, C.C.O.; ALEXANDRE, P.B.D.; TIMÓTEO, R.P.; CATARINO, J.S.; SALES-CAMPOS, H.; MACHADO, J.R.; RODRIGUES, D.B.R.; OLIVEIRA, C.J.; RODRIGUES, V. TNF-α blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines. Plos One 13(3): 1-13, 2018. SINGH, J.A.; FURST, D.E.; BHARAT, A.; CURTIS, J.R.; et al. Update of the 2008 American College of Rheumatology (ACR) Recommendations for the use of DiseaseModifying AntiRheumatic Drugs and Biologics in the treatment of Rheumatoid Arthritis (RA). Arthritis Care Research (Hoboken), 64(5): 625–39, 2012. SKARIAH, S.; MATTHEW KARMEN MCINTYRE; DANA G. MORDUE. Toxoplasma gondii: determinants of tachyzoite to bradyzoite conversion, Parasitology Research, 107 (2): 253–260, 2010. SMITH, D.A.; GERMOLEC, D.R. Introduction to immunology and autoimmunity. Environ Health Perspect.107(5): 661–665, 1999. SPLENDORE, A. — Sur un nouveau protozoaire parasite du lapin. Bull. Soc. Path. Exot. 2:462-464, 1909. SUZUKI, Y.; ORELLANA, M.A.; SCHREIBER, R.D.; REMINGTON, J.S. Interferongamma: the major mediator of resistance against Toxoplasma gondii. Science, 240:516–518, 1988. TENTER, A.M.; HECKEROTH, A.R.; WEISS. Toxoplasma gondii: from animals to humans. International Journal for Parasitology, 30, 1217–1258, 2000. VILLARD, O.; CIMON, B.; L'OLLIVIER, C.; FRICKER-HIDALGO, H.; GODINEAU, N.; HOUZE, S.; PARIS, L.; PELLOUX, H.; VILLENA, I.; CANDOLFI E. Serological diagnosis of Toxoplasma gondii infection: Recommendations from the French National Reference Center for Toxoplasmosis. Diagnostic Microbiology Infectious Diseases, 84: 22-23, 2016. WALCHER, D.L. et al. Toxoplasmose gestacional: uma revisão. Revista Brasileira de Análises Clínicas – RBAC, 49 (4): 323-327, 2017. WIELAARD, l.F.; GRUIJTHUIJSEN, H.V.; DUERMEYER, W. et al. Diagnosis of acute toxoplasmosis by an enzyme immunoassay for specific immunoglobulin M antibodies. Journal of Clinical Microbiology, 17:981-987, 1983. YAP, G.S.; SCHARTON-KERSTEN, T.; CHAREST, H.; SHER, A. Decreased resistance of TNF receptor p55- and p75deficient mice to chronic toxoplasmosis despite normal activation of inducible nitric oxide synthase in vivo. Journal of immunology, 160 (3):1340–1345, 1998. YAROVINSKY, F. Toll-Like Receptors and Their Role in Host Resistance to Toxoplasma gondii, Immunology Letters, 119, (1-2): 17-21, 2008. YAROVINSKY, F.; ZHANG, D.; ANDERSEN, J.F. et al., TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science, 308:1626, 2005. YASUI, K. Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNFalpha reagents. Pediatric Rheumatology Online Journal, 12: 45, 2014. YOUNG, J.D.; MCGWIRE, B.S. Infliximab and reactivation of cerebral toxoplasmosis. New England Journal of Medicine, 353(14):1530-1, 2005 | por |
| dc.rights | Acesso Aberto | por |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
| dc.subject | Bloqueadores de TNF-α. | por |
| dc.subject | Imunoglobulinas. | por |
| dc.subject | Toxoplasma-gondii. | por |
| dc.subject | Imunossupressão terapêutica. | por |
| dc.subject | Toxoplasmose. | por |
| dc.subject | TNF-α blockers. | eng |
| dc.subject | Immunoglobulins. | eng |
| dc.subject | Toxoplasma-gondii. | eng |
| dc.subject | Therapeutic immunosuppression. | eng |
| dc.subject | Toxoplasmosis. | eng |
| dc.subject.cnpq | Imunologia | por |
| dc.title | Avaliação do perfil sorológico anti-Toxoplasma gondiII de pacientes com doenças autoimunes em uso de medicamentos imunomoduladores biológicos e sintéticos | por |
| dc.type | Dissertação | por |
| Aparece nas coleções: | Programa de Pós-Graduação em Ciências da Saúde | |
Arquivos associados a este item:
| Arquivo | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| Dissert Aline C L Marques.pdf | Dissert Aline C L Marques | 945,5 kB | Adobe PDF |  Visualizar/Abrir |
Este item está licenciada sob uma Licença Creative Commons
